Cancer Vaccine
Recepteur d'origine nantais (RON) tyrosine kinase is molecular target for epithelial cancers
Published in Vaccine Weekly, August 9th, 2006
According to a study from China, "Recepteur d'origine nantais (RON) belongs to a subfamily of receptor tyrosine kinases (RTK) with unique expression patterns and biological activities. RON is activated by a serum-derived growth factor macrophage stimulating protein (MSP). The RON gene transcription is essential for embryonic development and critical in regulating certain physiological processes. Recent studies have indicated that altered RON expression contributes significantly to cancer progression and malignancy."
"In primary tumors, such as colon and breast cancers,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-08-09)
More Articles from Vaccine Weekly
- Breast Cancer Vaccine
CIITA-induced MHC class II expression leads to breast tumor rejection - Cancer Vaccine
Dendritic cell vaccine induces T cell response against tongue squamous carcinoma - Contraception
Sperm DNA vaccine has contraceptive effects in female mice - Pancreatic Cancer
Connective tissue growth factor-specific monoclonal antibodies inhibit pancreatic tumors - Vaccine Efficacy
IL-2 signals during priming are required for expansion of CD8+ memory T cells - Adrenocortical Cancer
Adrenocortical carcinoma management depends on better understanding of molecular pathogenesis - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
